Results 201 to 210 of about 30,282,823 (310)

Designing for impact: a case study of UTHSC's research impact challenge. [PDF]

J Med Libr Assoc
McDonald JN, Holt AL.
europepmc   +1 more source

Embedded Research: Possibilities for Learning Health Systems Comment on "'We're Not Providing the Best Care if We are Not on the Cutting Edge of Research': A Research Impact Evaluation at a Regional Australian Hospital and Health Service". [PDF]

Int J Health Policy Manag, 2023
Archibald MM.
europepmc   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Evaluation of the Relative Citation Ratio Among Academic Orthopedic Hand Surgeons: A Novel Measure of Research Impact. [PDF]

Cureus, 2022
McNamara JK, Henderson MN, Sudah SY, Faccone RD, Michel CR, Dijanic C, Menendez ME, Ruskin JB.   +7 more
europepmc   +1 more source

Reducing research waste and improving research impact

Australian and New Zealand Journal of Public Health, 2015
Luke Wolfenden, Anna Ziersch, Priscilla Robinson, John Lowe, John Wiggers   +4 more
openaire   +3 more sources

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Factors influencing the research impact in cancer research: a collaboration and knowledge network analysis. [PDF]

Health Res Policy Syst
Liao S, Lavender C, Zhai H.
europepmc   +1 more source

Building a culture of research impact assessment within the agro-food research organizations. [PDF]

Agric Food Econ, 2021
Guesmi B, Gil JM.
europepmc   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

From Philanthropy to Clinical Care through Research: Impact of the Norman Saunders Complex Care Initiative. [PDF]

Children (Basel), 2022
Macarthur C, Cohen E, Adams S, Buchanan F, Saunders NR, Friedman JN.   +5 more
europepmc   +1 more source